Straits Times Index
3,303.66 +12.96 (+0.39%) S&P 500
5,226.70 +4.02 (+0.08%) Dow
39,580.41 +67.57 (+0.17%) Nasdaq
16,376.95 +36.08 (+0.22%) Bitcoin USD
62,813.17 +1,648.44 (+2.70%) CMC Crypto 200
1,297.38 +37.17 (+2.95%)
Eli Lilly and Co (LLY.SG)
| Previous close | 708.50 |
| Open | 704.70 |
| Bid | 698.60 x 100000 |
| Ask | 699.30 x 100000 |
| Day's range | 698.50 - 709.20 |
| 52-week range | 387.60 - 738.00 |
| Volume | |
| Avg. volume | 448 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Lilly Declares Second-Quarter 2024 Dividend
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on outstanding common stock.
- PR Newswire
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2024.
- PR Newswire
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies. AHI records the number of times a person's breathing shows a restricted or complete block of airflow per hour of sleep and is used to evaluate the sever
